Skip to main content
Clinical Trials/NCT02457507
NCT02457507
Completed
Phase 4

Vitamin B12 Supplement to Prevent Cognitive Decline

Chinese University of Hong Kong1 site in 1 country271 target enrollmentAugust 2011

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Cognitive Decline
Sponsor
Chinese University of Hong Kong
Enrollment
271
Locations
1
Primary Endpoint
Change in Clinical Dementia Rating Scale (CDR)
Status
Completed
Last Updated
10 years ago

Overview

Brief Summary

Background: Older diabetic people are at greater risk of cognitive decline than non-diabetic people. Vitamin B12 deficiency in older people is associated with cognitive impairment and Alzheimer's disease. Vitamin B12 deficiency may therefore contribute to cognitive decline in older diabetic people.

Objective: To determine whether the correction of mild vitamin B12 deficiency in cognitively normal older diabetic people reduces the incidence of cognitive decline.

Design: randomized, double blind, placebo controlled trial Subject: Cognitively normal diabetic outpatients aged 70 years or older with plasma vitamin B12 150-300 pmol/L in medical and family medicine/ general outpatient clinics.

Procedure: After excluding those with clinical manifestations of vitamin B12 deficiency and without family member who can reliably inform on cognitive functioning (personal contact at least once a week), eligible patients will be invited to participate in this clinical trial. After obtaining written consent, research assistant (RA) will record demographic and clinical information from the subjects and perform neuropsychological tests - 1. Clinical dementia rating scale (CDR), 2. neurocognitive test battery (see below) 3. Chinese Mini mental state examination (MMSE), 4. Geriatric depression scale (GDS). Fasting blood will be taken for serum methylmalonic acid (MMA). Those with cognitive impairment and significant comorbidities will be excluded.

264 eligible subjects will be randomly assigned to take either two Vitamin B12 500 microgram or two identical looking placebo tablets once daily for 27 months.

All subjects or family caregivers are reviewed in the research clinic every 12 weeks in which the research assistant performs a pill count and dispenses the trial tablets. At 9 monthly intervals, the subjects will have neurocognitive test battery repeated at research clinic. CDR will be repeated at month 18 and 27. At month 9 and 27, fasting serum MMA and vitamin B12 will be repeated.

Registry
clinicaltrials.gov
Start Date
August 2011
End Date
January 2016
Last Updated
10 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Timothy Kwok

Professor

Chinese University of Hong Kong

Eligibility Criteria

Inclusion Criteria

  • \>/= 70 years old
  • B12: 150 - 300 pmol/L
  • Caregiver (personal contact at least once a week)

Exclusion Criteria

  • Peripheral neuropathy
  • Anaemia (Hb\<10 g/dl)
  • Renal failure (creatinine \> 150 µmol/L

Outcomes

Primary Outcomes

Change in Clinical Dementia Rating Scale (CDR)

Time Frame: Change from baseline in CDR at month 9, 18, 27

Secondary Outcomes

  • Change in serum homocysteine (µmol/L)(Change from baseline in serum homocysteine at month 9, 27)
  • Change in Neurocognitive test battery (NTB) score(Change from baseline in NTB score at month 9, 18, 27)

Study Sites (1)

Loading locations...

Similar Trials